Patents Assigned to Pieris AG
  • Publication number: 20160280747
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. A like immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Application
    Filed: April 6, 2016
    Publication date: September 29, 2016
    Applicant: Pieris AG
    Inventors: ARNE SKERRA, Gerald Beste, Frank Schmidt, Thomas Stibora
  • Publication number: 20160256525
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Application
    Filed: December 28, 2015
    Publication date: September 8, 2016
    Applicant: Pieris AG
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Publication number: 20160200780
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Application
    Filed: December 14, 2015
    Publication date: July 14, 2016
    Applicant: PIERIS AG
    Inventors: GABRIELE MATSCHINER, ANDREAS HOHLBAUM, MARTIN HUELSMEYER, STEFAN TRENTMANN
  • Patent number: 9260492
    Abstract: Described are specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins include muteins of a lipocalin protein, such as lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: February 16, 2016
    Assignee: Pieris AG
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Kristian Jensen
  • Patent number: 9221887
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 29, 2015
    Assignee: Pieris AG
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Patent number: 9221885
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) also known as CD152, which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: December 29, 2015
    Assignee: Pieris AG
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Arne Skerra
  • Publication number: 20150369821
    Abstract: The present invention relates to lipocalin-mutein assays for measuring hepcidin concentration as well as methods preparing and utilizing and kits leveraging the lipocalin-mutein assays.
    Type: Application
    Filed: February 5, 2014
    Publication date: December 24, 2015
    Applicant: PIERIS AG
    Inventors: Stefan TRENTMANN, Rachida SIHAM BEL AIBA, Andrea ALLERSDORFER, Nicole ANDERSEN, Andreas HOHLBAUM
  • Patent number: 9212208
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: December 15, 2015
    Assignee: Pieris AG
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
  • Publication number: 20150344538
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.
    Type: Application
    Filed: November 20, 2013
    Publication date: December 3, 2015
    Applicant: PIERIS AG
    Inventors: Marlon HINNER, Laurent AUDOLY, Martin HUELSMEYER, Kristian JENSEN, Gabriele MATSCHINER, Shane OLWILL, Alexander WIEDENMANN, Andrea ALLERSDORFER
  • Publication number: 20150291675
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.
    Type: Application
    Filed: May 6, 2015
    Publication date: October 15, 2015
    Applicant: PIERIS AG
    Inventors: STEFAN TRENTMANN, GABRIELE MATSCHINER, ARNE SKERRA, ANDREAS HOHLBAUM, MARTIN HUELSMEYER, HENDRIK GILLE, HANS-JUERGEN CHRISTIAN, KRISTIAN JENSEN, RACHIDA SIHAM BEL AIBA
  • Publication number: 20150283207
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Application
    Filed: March 23, 2015
    Publication date: October 8, 2015
    Applicant: PIERIS AG
    Inventors: Andreas HOHLBAUM, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfield, Hans-Juergen Christian
  • Publication number: 20150284435
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic lipocalin muteins directed against Glypican-3 (GPC-3). The invention also relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the invention also is directed to pharmaceutical compositions comprising such muteins and practical uses of these lipocalin muteins. In addition, the present invention provides methods of using muteins of human lipocalin 2 (Lcn2 or NGAL) for target-specific delivery of therapeutic moieties or detectable labels to cells expressing GPC-3, and related therapeutic and diagnostic utilization.
    Type: Application
    Filed: May 21, 2013
    Publication date: October 8, 2015
    Applicant: PIERIS AG
    Inventor: Klaus Kirchfield
  • Patent number: 9051382
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: June 9, 2015
    Assignee: PIERIS AG
    Inventors: Stefan Trentmann, Gabriele Matschiner, Arne Skerra, Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Hans-Juergen Christian, Kristian Jensen, Rachida Siham Bel Aiba
  • Patent number: 8986951
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: March 24, 2015
    Assignee: Pieris AG
    Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
  • Publication number: 20140288008
    Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Applicants: Daiichi Sankyo Company, Limited, Pieris AG
    Inventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
  • Publication number: 20140080177
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Application
    Filed: August 20, 2013
    Publication date: March 20, 2014
    Applicant: Pieris AG
    Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
  • Patent number: 8536307
    Abstract: The invention relates to the production of novel proteins exhibiting binding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using genetic engineering methods. Like immunoglobulin, the anticalin thus obtained can be used to identify or bind molecular structures.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: September 17, 2013
    Assignee: Pieris AG
    Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
  • Patent number: 8313924
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: November 20, 2012
    Assignee: Pieris AG
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Publication number: 20120201873
    Abstract: The present invention relates to pharmaceutical compositions for the controlled release of lipocalin muteins and conjugates thereof with a moiety selected from the group consisting of a protein, protein domain, peptide, lipid, fatty acid, polysaccharide and/or an organic polymer that comprise said lipocalin mutein of conjugate thereof in combination with a biodegradable polymer. The invention further relates to a method for the controlled delivery of the lipocalin muteins or conjugates thereof, methods for the production of a controlled release formulation and the thus produced formulation.
    Type: Application
    Filed: August 5, 2010
    Publication date: August 9, 2012
    Applicant: PIERIS AG
    Inventors: Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Sankaram Bhima Mantripragada, Kathleen Marie Campbell
  • Patent number: 8158753
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: April 17, 2012
    Assignee: Pieris AG
    Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora